https://scholars.lib.ntu.edu.tw/handle/123456789/636694
標題: | Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial | 作者: | Merle, Philippe Kudo, Masatoshi Edeline, Julien Bouattour, Mohamed ANN-LII CHENG Chan, Stephen L Yau, Thomas Garrido, Marcelo Knox, Jennifer Daniele, Bruno Breder, Valeriy Lim, Ho Yeong Ogasawara, Sadahisa Cattan, Stéphane Chao, Yee Siegel, Abby B Martinez-Forero, Iván Wei, Ziwen Liu, Chih-Chin Finn, Richard S |
關鍵字: | Hepatocellular carcinoma; Long-term follow-up; Pembrolizumab; Programmed cell death protein 1 | 公開日期: | 九月-2023 | 卷: | 12 | 期: | 4 | 來源出版物: | Liver cancer | 摘要: | KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/636694 | ISSN: | 2235-1795 | DOI: | 10.1159/000529636 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。